NCT02739295

G-CSF in the Treatment of Toxic Epidermal Necrolysis

Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Liege · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial. Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.

Conditions

• Stevens - Johnson Syndrome

Interventions

Type	Name	Description
DRUG	recombinant granulocyte - colony stimulating factor
DRUG	NaCl 0.9%

Timeline

• Start date: 2016-07-01
• Primary completion: 2023-03-07
• Completion: 2023-03-07
• First posted: 2016-04-15
• Last updated: 2025-12-31

Locations

2 sites across 1 country: Belgium